Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

摘要: Background: The aim of this subgroup analysis the Mabthera International Trial Group study was to evaluate impact chemotherapy and rituximab in primary mediastinal B-cell lymphoma (PMBCL) comparison other diffuse large (DLBCL). Methods: Patients were randomly assigned six cycles CHOP-like regimens with or without rituximab. Results: Of 824 patients enrolled, 87 had PMBCL 627 types DLBCL. Rituximab increased rates complete remission (unconfirmed) both (from 54% 80%, P = 0.015) DLBCL 72% 87%, < 0.001). In PMBCL, virtually eliminated progressive disease (PD) (2.5% versus 24%, 0.001), whereas rituximab, PD more frequent than (24% 10%, 0.010). With a median observation time 34 months, 3-year event-free survival (EFS) improved by for (78% 52%, 0.012) (81% 61%, Overall benefit similar (93% 85%, 0.001) (89% 78%, 0.158). Conclusion: young (age-adjusted Prognostic Index 0–1), added increases response rate EFS same extent as combination CHOP is an effective treatment good prognosis features.